Skip Navigation
 
 
 
 xxx
 
Print This Page
Share this page: More
 

Current Clinical Trials for Leukemia

Search below for current open leukemia clinical trials.

AML Clinical Trials
ALL Clinical Trials
MDS Clinical Trials
MPD Clincial Trials
CML Clinical Trials

AML Clinical Trials

Newly Diagnosed – Adults

Phase II trial of High Dose Lenalidomide in Patients with MDS and AML with Trilineage Dysplasia (AML-TLD)
Purpose: To determine and describe toxicity of higher doses of lenalidomide in patients with MDS and AML-TLD who do not harbor the 5q31.1.deletion and those who have such a deletion but have failed to respond to standard dose lenalidomide.
Eligibility: Patients may not have received prior AML induction chemotherapy or stem cell transplant.
Read more

Randomized Phase II Trial of timed Sequential Therapy (TST) with Alvocidib (Flavopiridol), ara-C and mitoxantrone (FLAM) vs. "7+3" for Adults age 70 and Under with Newly Diagnosed Acute Myelogenous Leukemia (AML)
Purpose: The purpose of this research study is to compare two different chemotherapy regimens to try to find out which way might be safer and/or more effective against AML.
Eligibility: Tumor Types: All Adults age greater than 18 years and less than 70 years with Newly Diagnosed, Intermediate Risk or Poor-Risk AML. Read more

A Phase I Study of AC220 (A2689) in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia
Purpose: In this trial, we are giving AC220 with the standard chemotherapy (daunorubicin and cytarabine) for AML to learn about its side effects and toxicities, and to see if we can improve a chance of getting a remission, as well as improve the chance that patients who receive it will eventually be cured.
Eligibility: To join the study, you must have AML, and have received NO prior treatment for your AML. You must be between 18 and 60 years old. Subjects with both a positive and negative FLT3-ITD mutation status are eligible. Additionally, you must have adequate liver and kidney function, as well as a good performance status (meaning, you can perform activities of daily living by yourself). Read more

Elderly

A Randomized Phase II Trial to Simultaneously Evaluate Two Schedules of the Histone Deacetylase Inhibitor Entinostat in Combination with 5-Azacytidine (5AC, NSC 102816) in Elderly Patients with Acute Myeloid Leukemia (AML)
Purpose: Patients with AML who are greater than 60 years old and unable to tolerate or decline cytotoxic chemotherapy or patients who have relapsed despite one prior regimen.
Eligibility: AML patients, de novo, treatment related, or secondary AML 60 years old or older. No prior therapy with demethylating agents in the last 1 year. Read more

Phase II Trial with Safety Run-in of MEK Inhibitor MSC1936369B in Subjects with Poor Prognosis Acute Myeloid Leukemia and Other Hematological Malignancies
Purpose: To assess the anti-leukemic activity of two regimens of AS703026 in older subjects with newly diagnosed poor prognosis Acute Myeloid Leukemia (AML) who are not candidates for intensive chemotherapy.
Eligibility: Primary or secondary AML who meet at least one of the following conditions. Read more

A Phase 1 Study of the PARP Inhibitor ABT-888 in Combination with Temozolomide in Acute Leukemias
Purpose: To evaluate the feasibility, safety, and toxicity of administering ABT-888 in combination with temozolomide in patients with acute leukemias.
Eligibility: Untreated AML in adults 60 years of age and older who are not candidates for induction chemotherapy due to poor-risk features including adverse cytogenetics or molecular markers (FLT3 ITD+), or are unwilling to receive intensive induction chemotherapy. Read more

Phase 2 Trial of R115777 in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Purpose: To determine the complete remission (CR) rate in AML patients prospectively selected for R115777R115777 (ZARNESTRA) treatment on the basis of a 2-gene signature (RASGRP1:APTX ratio) in bone marrow aspirates.
Eligibility: Older than 65 with previously untreated AML (de novo or secondary), deemed unsuitable for or refuses standard induction chemotherapy. Read more

AML

Relapsed or Refractory

A Phase 1 Study of ABT-888 in Combination with Topotecan plus Carboplatin for Relapsed and Refractory Acute Leukemias and High-Risk Myelodyplasias and Myeloproliferative Disorders
Purpose:  To determine tolerability, toxicity and response rates of ABT-888 administered with Topotecan with Carboplatin.
Eligibility: Inclusion Criteria Adults 18 years of age and older. Must be able to care for self. Organ Function Permitted: Serum Creatinine normal, or estimated creatinine clearance greater than 60 ml/min. Read more

Phase II Trial with Safety Run-in of MEK Inhibitor MSC1936369B in Subjects with Poor Prognosis Acute Myeloid Leukemia and Other Hematological Malignancies
Purpose: To assess the anti-leukemic activity of two regimens of AS703026 in older subjects with newly diagnosed poor prognosis Acute Myeloid Leukemia (AML) who are not candidates for intensive chemotherapy.
Eligibility: Primary or secondary AML who meet at least one of the following conditions. Read more

A Phase 1 Study of the PARP Inhibitor ABT-888 in Combination with Temozolomide in Acute Leukemias
Purpose: To evaluate the feasibility, safety, and toxicity of administering ABT-888 in combination with temozolomide in patients with acute leukemias.
Eligibility: Relapsed or refractory acute myelogenous leukemia (AML). APL that has failed ATRA, Arsenic and gemtuzumab. Read more

A Randomized Phase II Trial to Simultaneously Evaluate Two Schedules of the Histone Deacetylase Inhibitor Entinostat in Combination with 5-Azacytidine (5AC, NSC 102816) in Elderly Patients with Acute Myeloid Leukemia (AML)
Purpose: Patients with AML who are greater than 60 years old and unable to tolerate or decline cytotoxic chemotherapy or patients who have relapsed despite one prior regimen.
Eligibility: AML patients greater than 60 years old, relapsed despite one prior regimen. No prior therapy with demethylating agents in the last treatment. Read more

A Phase 1, Open-Label, Multicenter Study of MDX-1338/BMS936564 in Subjects with Relapsed/Refractory Acute Myelogenous Leukemia
Purpose: This is a Phase 1 study to determine the maximum tolerated dose of MDX-1338 in patients with relapsed/refractory AML
Eligibility: Diagnosis: Relapsed/refractory AML (APL excluded) unsuitable for standard therapy. If relapsed, no more than 2 relapses are allowed. Read more

AML Maintenance

A Pilot Study of Sorafenib in Patients with Acute Myeloid Leukemia as Peri-Transplant Remission Maintenance
Purpose: Determine the toxicity and safety of incorporation of Sorafanib into the pre or post transplant maintenance setting for three types of transplants.
Eligibility: Acute Myeloid leukemia with a FLT3 ITD. Read more

ALL Clinical Trials

Newly Diagnosed, untreated
J09112
Intensified Methotrexate, Nelarabine (Compound 506U78; IND# 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia
Purpose: The overall goal of this study is to see if we can increase the cure rate for T-cell ALL with acceptable side effects of therapy.
Eligibility: Patients must be between 1-30 years of age, newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) Patients shall have had no prior cytotoxic chemotherapy with the exception of steroids and/or IT cytarabine.  Read more

A Phase 1 Study of the PARP Inhibitor ABT-888 in Combination with Temozolomide in Acute Leukemias
Purpose: To evaluate the feasibility, safety, and toxicity of administering ABT-888 in combination with temozolomide in patients with acute leukemias.
Eligibility: Untreated ALL in adults 60 years of age and older who are not candidates for induction chemotherapy due to poor-risk features including adverse cytogenetics. Read more

ES0805 Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) with or without Allogeneic Stem Cell Transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL)
Purpose: To see whether the relapse-free survival of patients after this treatment is sufficiently high to warrant further investigation.
Eligibility: Newly diagnosed Ph+ ALL, excluding M0 AML, mixed lineage leukemia, and L3 (Burkitts). Allo BMT if eligible. Read more

ALL Clinical Trials

Relapsed/Refractory

A Phase 1 Study of ABT-888 in Combination with Topotecan plus Carboplatin for Relapsed and Refractory Acute Leukemias and High-Risk Myelodyplasias and Myeloproliferative Disorders
Purpose: To determine tolerability, toxicity and response rates of ABT-888 administered with Topotecan with or without Carboplatin
Eligibility: Primary refractory, or relapsed/refractory at least to 1 regimen w/ < 3 prior therapies. Read more

Phase II Trial with Safety Run-in of MEK Inhibitor MSC1936369B in Subjects with Poor Prognosis Acute Myeloid Leukemia and Other Hematological Malignancies
Purpose: Primary objectives of this protocol include: Safety run-in part To determine the maximum tolerated dose (MTD), for each of the two regimens of AS703026 in subjects with advanced hematological malignancies.
Eligibility: Relapsed, refractory or intolerant to standard treatment. Read more

A Phase 1 Study of the PARP Inhibitor ABT-888 in Combination with Temozolomide in Acute Leukemias
Purpose: To evaluate the feasibility, safety, and toxicity of administering ABT-888 in combination with temozolomide in patients with acute leukemias.
Eligibility: Relapsed or refractory pre-B- or T-cell acute lymphoblastic leukemia (ALL). Read more

MDS Clinical Trials

Phase II trial of High Dose Lenalidomide in Patients with MDS and AML with Trilineage Dysplasia (AML-TLD)
Purpose: The primary endpoint is hematologic response rate (defined by IWG 2006 response criteria) following administration of 2 - 4 cycles of lenalidomide 15 mg.
Eligibility: MDS or MDS/AML Patients must not have received any other treatment for their disease, including hematopoietic growth factors, within three weeks of beginning the trial ECOG performance status of 0, 1, or 2 at study entry.Read more

Phase II Trial with Safety Run-in of MEK Inhibitor MSC1936369B in Subjects with Poor Prognosis Acute Myeloid Leukemia and Other Hematological Malignancies
Purpose: Primary objectives of this protocol include: Safety run-in part to determine the maximum tolerated dose (MTD), for each of the two regimens of AS703026 in subjects with advanced hematological malignancies.
Eligibility: Subjects with myelodysplastic syndrome (MDS), IPSS Int-2 or high risk who are resistant or intolerant to standard treatment and not candidates for transplantation. Read more


MPD Clinical Trials

A Phase 1 Study of ABT-888 in Combination with Topotecan plus Carboplatin for Relapsed and Refractory Acute Leukemias and High-Risk Myelodyplasias and Myeloproliferative Disorders
Purpose: To determine tolerability, toxicity and response rates of ABT-888 administered with Topotecan with or without Carboplatin
Eligibility: Aggressive MPD with bone marrow blast greater than 5%. Read more

A Phase 1 Study of the PARP Inhibitor ABT-888 in Combination with Temozolomide in Acute Leukemias
Purpose: To define the maximum tolerated dose (MTD) and Recommended Phase II Dose (RP2D) of ABT-888 administered in combination with temozolomide in patients with acute leukemias.
Eligibility: Chronic Myelogenous Leukemia (CML) in accelerated or blastic phase: Patients must have failed (resistance/intolerance) at least 2 different TKIs or have a tation associated with resistance to TKIs (T315I). AML arising in the setting of antecedent myelodysplasia (MDS) or myeloproliferative disorder (MPD). Read more


CML Clinical Trials

A Phase 1 Study of the PARP Inhibitor ABT-888 in Combination with Temozolomide in Acute Leukemias
Purpose: To define the maximum tolerated dose (MTD) and Recommended Phase II Dose (RP2D) of ABT-888 administered in combination with temozolomide in patients with acute leukemias.
Eligibility: Chronic Myelogenous Leukemia (CML) in accelerated or blastic phase: Patients must have failed (resistance/intolerance) at least 2 different TKIs or have a tation associated with resistance to TKIs (T315I). AML arising in the setting of antecedent myelodysplasia (MDS) or myeloproliferative disorder (MPD). Read more

K562/GM-CSF Vaccination in Combination with Imatinib Mesylate as Booster for Chronic Myeloid Leukemia Patients Previously Vaccinated on Protocol J0345
Purpose: Determine whether a series of four K562/GM-CSF vaccinations (+/- imiquimod cream) can serve as an immunologic  booster.
Eligibility: Patients with AML who completed the entire protocol of J0345 and still have evidence of disease. Read more

A randomized phase II trial of Interferon + GM-CSF versus K562/GM-CSF vaccination in CML patients achieving a complete cytogenetic response to imatinib
Purpose: To determine whether sequential, combination therapy can improve clinical responses of single agent imatinib for patients with Ph+ CML in chronic phase in cytogenetic remission.
Eligibility: Complete cytogenetic response of CML to stable imatinib dose. Read more

Dasatinib (BMS-354825) Combined with SMO Inhibitor (BMS-833923; XL139) in CML with Resistance or Suboptimal Response to a Prior TKI
Purpose: The main purpose of this study is to test the safety of the combination of the drug dasatinib plus BMS-833923 (SMO inhibitor).
Eligibility: Chronic phase, or advanced allowed. No limit on prior treatment. Subjects must have resistance or suboptimal response to imatinib, dasatinib or nilotinib (see Inclusion criteria) and may not have a known T315I/A Abl-kinase mutation. Read more

 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer